Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-25-001810
Filing Date
2025-08-14
Accepted
2025-08-14 16:06:13
Documents
54
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q enzn-20250630x10q.htm   iXBRL 10-Q 760277
2 EX-4.1 enzn-20250630xex4d1.htm EX-4.1 23029
3 EX-31.1 enzn-20250630xex31d1.htm EX-31.1 13067
4 EX-32.1 enzn-20250630xex32d1.htm EX-32.1 7493
  Complete submission text file 0001410578-25-001810.txt   3222557

Data Files

Seq Description Document Type Size
5 EX-101.SCH enzn-20250630.xsd EX-101.SCH 29663
6 EX-101.CAL enzn-20250630_cal.xml EX-101.CAL 20211
7 EX-101.DEF enzn-20250630_def.xml EX-101.DEF 87702
8 EX-101.LAB enzn-20250630_lab.xml EX-101.LAB 219727
9 EX-101.PRE enzn-20250630_pre.xml EX-101.PRE 161667
57 EXTRACTED XBRL INSTANCE DOCUMENT enzn-20250630x10q_htm.xml XML 308931
Mailing Address 20 COMMERCE DRIVE, SUITE 135 CRANFORD NJ 07016
Business Address 20 COMMERCE DRIVE, SUITE 135 CRANFORD NJ 07016 732-980-4500
ENZON PHARMACEUTICALS, INC. (Filer) CIK: 0000727510 (see all company filings)

EIN.: 222372868 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-12957 | Film No.: 251218835
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)